Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.
2.

Renal brush border membrane vesicle aminoglycoside binding and nephrotoxicity.

Todd JH, Hottendorf GH.

J Pharmacol Exp Ther. 1995 Jul;274(1):258-63.

PMID:
7616406
3.

Tobramycin gender-related nephrotoxicity in Fischer but not Sprague-Dawley rats.

Goodrich JA, Hottendorf GH.

Toxicol Lett. 1995 Jan;75(1-3):127-31.

PMID:
7863519
4.

Effects of polyaspartic acid on pharmacokinetics of tobramycin in two strains of rat.

Reinhard MK, Bekersky I, Sanders TW Jr, Harris BJ, Hottendorf GH.

Antimicrob Agents Chemother. 1994 Jan;38(1):79-82.

5.

Lack of in vivo evidence of a cytochrome P450 metabolite participating in aminoglycoside nephrotoxicity.

Sanders TW Jr, Reinhard MK, Jollow DJ, Hottendorf GH.

Biochem Pharmacol. 1993 Feb 9;45(3):780-2.

PMID:
8442776
6.

Differences in the sensitivity of Fischer and Sprague-Dawley rats to aminoglycoside nephrotoxicity.

Reinhard MK, Hottendorf GH, Powell ED.

Toxicol Pathol. 1991;19(1):66-71.

PMID:
2047709
7.

Comparative toxicities of cephalosporin antibiotics in a rabbit kidney cell line (LLC-RK1).

Williams PD, Laska DA, Tay LK, Hottendorf GH.

Antimicrob Agents Chemother. 1988 Mar;32(3):314-8.

8.

Single-dose and multiple-dose intravenous toxicity studies of BMY-25282 in rats.

Bregman CL, Comereski CR, Buroker RA, Hirth RS, Madissoo H, Hottendorf GH.

Fundam Appl Toxicol. 1987 Jul;9(1):90-109.

PMID:
3622965
9.

An in vitro model for assessing muscle irritation due to parenteral antibiotics.

Williams PD, Masters BG, Evans LD, Laska DA, Hottendorf GH.

Fundam Appl Toxicol. 1987 Jul;9(1):10-7.

PMID:
3622955
10.

Correlation between renal membrane binding and nephrotoxicity of aminoglycosides.

Williams PD, Bennett DB, Gleason CR, Hottendorf GH.

Antimicrob Agents Chemother. 1987 Apr;31(4):570-4.

11.

Role of desacetylation in the detoxification of cephalothin in renal cells in culture.

Hottendorf GH, Laska DA, Williams PD, Ford SM.

J Toxicol Environ Health. 1987;22(1):101-11.

PMID:
3612832
12.

Risk assessment problems in chemical oncogenesis.

Hottendorf GH.

Prog Drug Res. 1987;31:257-72. Review. No abstract available.

PMID:
3326032
13.

[3H]gentamicin uptake in brush border and basolateral membrane vesicles from rat kidney cortex.

Williams PD, Hottendorf GH.

Biochem Pharmacol. 1986 Jul 1;35(13):2253-6. No abstract available.

PMID:
3729980
14.

Inhibition of renal membrane binding and nephrotoxicity of aminoglycosides.

Williams PD, Hottendorf GH, Bennett DB.

J Pharmacol Exp Ther. 1986 Jun;237(3):919-25.

PMID:
3754895
15.

Pain on injection and muscle irritation: a comparison of animal models for assessing parenteral antibiotics.

Comereski CR, Williams PD, Bregman CL, Hottendorf GH.

Fundam Appl Toxicol. 1986 Feb;6(2):335-8.

PMID:
3699322
16.

Functional-morphologic correlations in assessing renal toxicity.

Hottendorf GH.

Toxicol Pathol. 1986;14(1):123-8.

PMID:
3715327
17.

Aminoglycoside nephrotoxicity.

Hottendorf GH, Williams PD.

Toxicol Pathol. 1986;14(1):66-72. Review.

PMID:
3520781
18.

Toxic factors limiting the use of anticancer agents.

Hottendorf GH.

Chemioterapia. 1985 Oct;4(5):383-7.

PMID:
4075433
19.

Effect of cisplatin on organic ion transport in membrane vesicles from rat kidney cortex.

Williams PD, Hottendorf GH.

Cancer Treat Rep. 1985 Jul-Aug;69(7-8):875-80.

PMID:
3160462
20.

Effect of cephalosporins on organic ion transport in renal membrane vesicles from rat and rabbit kidney cortex.

Williams PD, Hitchcock MJ, Hottendorf GH.

Res Commun Chem Pathol Pharmacol. 1985 Mar;47(3):357-71.

PMID:
2986254
21.

Inhibition of renal membrane binding and nephrotoxicity of gentamicin by polyasparagine and polyaspartic acid in the rat.

Williams PD, Hottendorf GH.

Res Commun Chem Pathol Pharmacol. 1985 Feb;47(2):317-20.

PMID:
3838817
22.

Carcinogenicity testing of antitumor agents.

Hottendorf GH.

Toxicol Pathol. 1985;13(3):192-9.

PMID:
4070930
23.

Review and evaluation of the NCI/NTP carcinogenesis bioassays.

Hottendorf GH, Pachter IJ.

Toxicol Pathol. 1985;13(2):141-6. Review.

PMID:
3901224
24.

Evaluation of the bioavailability of sarpicillin, the methoxymethyl ester of hetacillin, in humans.

Stavchansky S, Pearlman RS, Van Harken DR, Smyth RD, Hottendorf GH, Martin A, Newburger J, Schneider LW.

J Pharm Sci. 1984 Feb;73(2):169-73.

PMID:
6707877
25.

The toxicological evaluation of tallysomycin s10b--biosynthetic tallysomycin derivative.

Buroker RA, Comereski CR, Barnett D, Hirth RS, Madissoo H, Hottendorf GH.

Drug Chem Toxicol. 1984;7(3):259-72.

PMID:
6203697
26.

The toxicologic evaluation of marcellomycin--an antineoplastic anthracycline antibiotic.

Buroker RA, Johnson DF, Comereski CR, Hirth RS, Madissoo H, Hottendorf GH.

Drug Chem Toxicol. 1983;6(1):21-40.

PMID:
6861661
27.

Nonparallel nephrotoxicity dose-response curves of aminoglycosides.

Hottendorf GH, Barnett D, Gordon LL, Christensen EF, Madissoo H.

Antimicrob Agents Chemother. 1981 Jun;19(6):1024-8.

28.

Human pharmacokinetics and disposition of sarmoxicillin, a lipophilic amoxicillin prodrug.

Smyth RD, Pfeffer M, Van Harken DR, Cohen A, Hottendorf GH.

Antimicrob Agents Chemother. 1981 Jun;19(6):1004-12.

29.

Preliminary studies of the pharmacokinetics of talisomycin in the rhesus monkey.

Van Harken DR, Smyth RD, Lee FH, Strong JE, Hottendorf GH.

Res Commun Chem Pathol Pharmacol. 1981 Mar;31(3):403-17.

PMID:
6166971
30.

Bioavailability and metabolism of potassium phosphanilate in laboratory animals and humans.

Lee FH, Van Harken DR, Vasiljev M, Smyth RD, Hottendorf GH.

Antimicrob Agents Chemother. 1980 Nov;18(5):746-52.

31.

Comparative low-dose nephrotoxicities of gentamicin, tobramycin, and amikacin.

Hottendorf GH, Gordon LL.

Antimicrob Agents Chemother. 1980 Jul;18(1):176-81.

32.

Application of pharmacokinetics and biopharmaceutics in the design of toxicological studies.

Smyth RD, Hottendorf GH.

Toxicol Appl Pharmacol. 1980 Apr;53(2):179-95. No abstract available.

PMID:
7394763
33.

Comparative pharmacokinetics of ceforanide (BL-S786R) and cefazolin in laboratory animals and humans.

Lee FH, Pfeffer M, Van Harken DR, Smyth RD, Hottendorf GH.

Antimicrob Agents Chemother. 1980 Feb;17(2):188-92.

34.

Biological disposition of 8-methoxsalen in rat and man.

Smyth RD, Van Harken DR, Pfeffer M, Nardella PA, Vasiljev M, Pinto JS, Hottendorf GH.

Arzneimittelforschung. 1980;30(10):1725-30. No abstract available.

PMID:
7192111
35.

Clinical pharmacokinetics and safety of high doses of ceforanide (BL-S786R) and cefazolin.

Smyth RD, Pfeffer M, Glick A, Van Harken DR, Hottendorf GH.

Antimicrob Agents Chemother. 1979 Nov;16(5):615-21.

36.

Evaluation of the availability of drugs incorporated in rat laboratory diet.

Smyth RD, Gaver RC, Dandekar KA, Van Harken DR, Hottendorf GH.

Toxicol Appl Pharmacol. 1979 Sep 30;50(3):493-9. No abstract available.

PMID:
516062
37.

Comparative absorption following the administration of a drug to rats by oral gavage and incorporation in the diet.

Van Harken DR, Hottendorf GH.

Toxicol Appl Pharmacol. 1978 Feb;43(2):407-10. No abstract available.

PMID:
635927
38.

Comparative pharmacokinetics and metabolism of cephapirin in laboratory animals and humans.

Cabana BE, van Harken DR, Hottendorf GH.

Antimicrob Agents Chemother. 1976 Aug;10(2):307-17.

39.

The role of the kidney in the elimination of cephapirin in man.

Cabana BE, Van Harken DR, Hottendorf GH, Doluisio JT, Griffen WO Jr, Bourne DW, Dittert LW.

J Pharmacokinet Biopharm. 1975 Dec;3(6):419-38. No abstract available.

PMID:
1206478
40.

Comparative plasma bactericidal activity of cephapirin and cefazolin.

Hottendorf GH, Price KE, Van Harken DR.

Curr Ther Res Clin Exp. 1975 Aug;18(2):364-70. No abstract available.

PMID:
809250
41.

New preclinical safety evaluation for single-dose clinical pharmacology.

Hottendorf GH, Madisoo H, Van Harken DR.

Toxicol Appl Pharmacol. 1974 May;28(2):323-7. No abstract available.

PMID:
4212198
42.

Lesions of spontaneous subclinical disease in Beagle dogs.

Hottendorf GH, Hirth RS.

Vet Pathol. 1974;11(3):240-58. No abstract available.

PMID:
4478041
43.

Ototoxicity studies with BB-K8, a new semisynthetic aminoglycoside antibiotic.

Reiffenstein JC, Holmes SW, Hottendorf GH, Bierwagen ME.

J Antibiot (Tokyo). 1973 Feb;26(2):94-100. No abstract available.

44.

Canine mastocytoma--a review of clinical aspects.

Hottendorf GH, Nielsen SW.

J Am Vet Med Assoc. 1969 Apr 15;154(8):917-24. No abstract available.

PMID:
4975997
45.

Spontaneous nephroblastomas in laboratory rats.

Hottendorf GH, Ingraham KJ.

J Am Vet Med Assoc. 1968 Oct 1;153(7):826-9. No abstract available.

PMID:
4300604
46.

Pathologic report of 29 necropsies on dogs with mastocytoma.

Hottendorf GH, Nielsen SW.

Pathol Vet. 1968;5(2):102-21. No abstract available.

PMID:
4970397
47.

Pathologic survey of 300 extirpated canine mastocytomas.

Hottendorf GH, Nielsen SW.

Zentralbl Veterinarmed A. 1967 Apr;14(3):272-81. No abstract available.

PMID:
4967309
48.

Collagen necrosis in canine mastocytomas.

Hottendorf GH, Nielsen SW.

Am J Pathol. 1966 Sep;49(3):501-13. No abstract available.

49.

Acidophil adenoma of the pituitary gland and other neoplasms in a boxer.

Hottendorf GH, Nielsen SW, Lieberman LL.

J Am Vet Med Assoc. 1966 May 1;148(9):1046-50. No abstract available.

PMID:
4286973
50.

Ribonucleic acid in canine mast cell granules and the possible interrelationship of mast cells and plasma cells.

Hottendorf GH, Nielsen SW, Kenyon AJ.

Pathol Vet. 1966;3(3):178-89. No abstract available.

PMID:
4163619

Supplemental Content

Loading ...
Support Center